ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,917.11
      0.00%
      US Tech 100
      20,159.60
      0.16%
      Dow Jones
      43,408.47
      0.32%
      Brent Oil
      74.02
      1.62%
      Bitcoin
      98,085.34
      3.95%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Anavex Life Sciences Corporation (AVXL) Quote

      Anavex Life Sciences Corporation

      Anavex Life Sciences Corporation (AVXL)

      NASDAQ
      8.475
      0.23
      (2.85%)
      Closed November 20 4:00PM
      Delayed by 15 minutes
      8.475
      0.00
      ( 0.00% )
      Pre Market: 4:01AM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      8.475
      Bid
      8.45
      Ask
      8.69
      Volume
      2
      0.00 Day's Range 0.00
      3.25 52 Week Range 10.45
      Market Cap
      718.642M
      Previous Close
      8.475
      Open
      -
      Last Trade
      2
      @
      8.56
      Last Trade Time
      07:09:42
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      990,827
      Shares Outstanding
      84,795,517
      Dividend Yield
      -
      PE Ratio
      -15.12
      Earnings Per Share (EPS)
      -0.56
      Revenue
      -
      Net Profit
      -47.51M

      About Anavex Life Sciences Corporation

      Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.anavex.com
      Headquarters
      Carson City, Nevada, USA
      Founded
      -
      Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was $8.48. Over the last year, Anavex Life Sciences shares have traded in a share price range of $ 3.25 to $ 10.45.

      Anavex Life Sciences currently has 84,795,517 shares outstanding. The market capitalization of Anavex Life Sciences is $718.64 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -15.12.

      Ask ADVFN Intelligence (AI)

      AVXL Latest News

      More News

      Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

      Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 Oral, once daily...

      October 31 2024
      GlobeNewswire Inc.

      ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition

      ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition     Miami, FL – October 23, 2024 -- InvestorsHub NewsWire – EmergingGrowth.com, a leading...

      October 23 2024
      InvestorsHub NewsWire

      Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

      Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are...

      October 17 2024
      GlobeNewswire Inc.

      ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management

      ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management  Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through...

      October 15 2024
      InvestorsHub NewsWire

      ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today

      ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today   Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through 2030     Miam...

      October 01 2024
      InvestorsHub NewsWire

      Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

      NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

      September 03 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 06 2024
      Edgar (US Regulatory)

      Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

      Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

      August 06 2024
      GlobeNewswire Inc.

      Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

      NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

      August 01 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      July 30 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.425-4.775280898888.99.247.1815112957.85852031CS
      43.07556.94444444445.410.455.2216502817.6509641CS
      122.55543.15878378385.9210.454.93019908276.70389226CS
      264.06592.17687074834.4110.453.5110467675.85850005CS
      521.475521.08007714846.999510.453.2512040115.8482864CS
      156-11.882-58.368128899220.35721.33.2511584118.74949639CS
      2606.025245.9183673472.4531.52.2131645410.43692024CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      WORXSCWorx Corporation
      $ 1.94
      (97.96%)
      		18.84M
      TRNRInteractive Strength Inc
      $ 5.71
      (59.05%)
      		857.64k
      PETWag Group Company
      $ 0.32
      (52.31%)
      		19.64M
      MGYRMagyar Bancorp Inc
      $ 19.00
      (43.50%)
      		7
      ESGROEnstar Group Ltd
      $ 28.00
      (40.92%)
      		28
      WSBFWaterstone Financial Inc
      $ 9.00
      (-40.98%)
      		4
      TRSTriMas Corporation
      $ 15.62
      (-40.79%)
      		3
      BCAXBicara Therapeutics Inc
      $ 11.00
      (-40.15%)
      		221
      XNCRXencor Inc
      $ 15.11
      (-36.30%)
      		2
      PYXSPyxis Oncology Inc
      $ 2.49
      (-34.82%)
      		259.56k
      AKTSAkoustis Technologies Inc
      $ 0.121
      (38.92%)
      		61.22M
      PETWag Group Company
      $ 0.3165
      (50.64%)
      		19.65M
      WORXSCWorx Corporation
      $ 1.96
      (100.00%)
      		18.85M
      XTKGX3 Holdings Company Ltd
      $ 0.0778
      (-13.56%)
      		10.91M
      CRKNCrown Electrokinetics Corporation
      $ 0.959
      (22.06%)
      		6.03M

      AVXL Discussion

      View Posts
      ExtremelyBullishZig ExtremelyBullishZig 33 minutes ago
      Great! Your wife says hello!
      👍️0
      ExtremelyBullishZig ExtremelyBullishZig 35 minutes ago
      Too bad that no one followed up to see that the story was false. Where is Ern today?
      👍️0
      ExtremelyBullishZig ExtremelyBullishZig 36 minutes ago
      It looks like it could maybe possibly work better than what is currently out there...it is what it is. Only a large properly planned trials would prove what you claim.
      👍️0
      ExtremelyBullishZig ExtremelyBullishZig 38 minutes ago
      The lost of people who look at things correctly. Stop taking psychedelics and you will see what is going on at Anavex.
      👍️0
      ExtremelyBullishZig ExtremelyBullishZig 40 minutes ago
      That isn't the point. If a company gives 10 "artificial timelines" annually, andaybe delivers on one of them, they cannot be trusted toanage properly...it means they don't know how to manage projects...it is a problem.

      If your wife constantly told you that she would be home from work by a certain time and was frequently an hour late without being promoted for working so hard...you may want to get a PI to find out who in the office she is "working on so hard". It has to do with trust.
      👍️0
      ExtremelyBullishZig ExtremelyBullishZig 46 minutes ago
      Same thing every year since they changed their company from a photo print shop to a drug company.

      They always lost ten items and possibly complete one withing the year that they list the catalyst.
      👍️0
      Investor2014 Investor2014 59 minutes ago
      As there is a lot talk about and use of LMMs like ChatGPT to 'help' understand e.g. the chance of approval for Anavex in AD. This talk gives an easy to follow and in depth understanding of the capabilities and limitations of this type of AI.

      👍️0
      Investor2014 Investor2014 1 hour ago
      Many here do indeed need to think much more as an investors in a speculative stock.

      Biotech is not for everyone.
      👍️0
      Investor2014 Investor2014 1 hour ago
      How is it going with that other biotech you have been pumping and the Investment Group?
      👍️0
      Investor2014 Investor2014 1 hour ago
      A blatant pumper and Missling apologist has been in plain sight for quite some time.
      👍️0
      Investor2014 Investor2014 1 hour ago
      Can you define "Artificial deadlines" and mention a handful of companies that successfully sell products and services grounded in setting artificial deadline?
      👍️0
      Steady_T Steady_T 7 hours ago
      How's that rent collection going? 🤣
      👍️ 2
      georgejjl georgejjl 8 hours ago
      When discussing "muscarinic M1" in relation to schizophrenia and PANSS, it refers to the potential therapeutic role of activating the M1 subtype of muscarinic acetylcholine receptors as a novel treatment strategy for schizophrenia, where improvements in symptoms can be measured using the Positive and Negative Syndrome Scale (PANSS), with research showing that targeting M1 receptors may lead to significant reductions in PANSS scores, indicating symptom improvement in patients with schizophrenia.

      Anavex 3-71 for the treatment of schizophrenia.

      Good luck and GOD bless,
      🧠 1
      ExtremelyBullishZig ExtremelyBullishZig 8 hours ago
      You believe George after the crap he pulls on a daily basis?
      👎️ 1 👺 1
      georgejjl georgejjl 8 hours ago
      I will predict that AVXL should exceed the $1 Billion market capitalization next week.

      Good luck and GOD bless,
      👍️0
      boi568 boi568 8 hours ago
      You are thinking more like a manager than an investor in a speculative stock.
      👍️ 4
      kund kund 8 hours ago
      Pumper Mayo pumping JPM news, which clown CEO posted on linkedin and X 3 month in advance, as if that is any indication. He pumped model picture with Elon's mom sometime back.
      👎️ 1 👺 1
      kund kund 8 hours ago
      You didn't get the memo? New video has surfaced, most probably from that tiny phase 2a trial, super responders.

      https://vimeo.com/1023753471
      👎️ 1 👺 1
      georgejjl georgejjl 8 hours ago
      An Australian TV news interview of Ern Heaven and his wife. Ern had Alzheimer's for over 2 years and was declining when he joined the Anavex phase 2a trial of Anavex 2-73. Over a period of a year on the drug, he first stabilized, and then improved. No other drug has ever helped an Alzheimer's patient improve.

      According to the 1 year trial results, 6 patients out of the initial 32 had "strong" reactions and showed improvements in one or more tests.



      Good luck and GOD bless,
      👍️0
      La Flaca La Flaca 9 hours ago
      We all stumbled onto this drug and didn’t really appreciate its value - starting with the Greek doctor and Missling. We all hung around because we hoped and prayed that it would work. Earlier and better execution would have been great but it is what it is. Looks like it works - better than anything that’s out there. Let’s hope it gets approved soon for the sake of the families afflicted with early alz. The money will come.
      🎯 1 👍️ 7
      crescentmotor crescentmotor 9 hours ago
      to have submitted something 4 months later than it nominally should have while moving the ball forward on none of the other programs is shameful.

      Dr. Missling is a proven underperformer. It's even worse than that as he has mislead AVXL's shareholders for a number of years with shameful shareholder guidance. I don't see how anyone with a properly functioning brain could argue that fact. It is nothing but horrible performance that the AD OLE data has not been released, not to mention the MAA. The word "slow" comes to mind that doesn't seem adequate. I will be very pleased if the MAA is filed and moves forward. After that, a partnership/buyout could occur and Dr. Missling would most likely be put out to pasture.
      👍️ 2 👎️ 1 👺 3
      bas2020 bas2020 9 hours ago
      You're absolutely correct. I saw through that masquerade for quite a while. Another to add to the list.
      👍️ 6
      georgejjl georgejjl 9 hours ago
      I predict that the dosing of all trial participants in the Phase 2 schizophrenia trial will be completed during or prior to December 2024.

      https://www.anavex.com/post/anavex-life-sciences-announces-encouraging-preliminary-biomarker-results-from-ongoing-phase-2-study#:~:text=NEW%20YORK%20–%20October%2017%2C%202024&text=Part%20A%20of%20the%20Phase,mg%20daily%20for%2010%20days.

      Good luck and GOD bless,
      🎯 1 👍️ 2
      ignatiusrielly35 ignatiusrielly35 10 hours ago
      An extremely subtle fudster has revealed himself or herself. 
      👍️ 7
      Hoskuld Hoskuld 10 hours ago
      Yes - to have submitted something 4 months later than it nominally should have while moving the ball forward on none of the other programs is shameful. It is a win - but is severe underperformance. For a pumper like yourself, everything is perfect, I get that.
      👍️ 4 👎️ 3 👺 6 ❌️ 2
      Hosai Hosai 10 hours ago
      "As you wrote, they will either submit the MAA or they won't...but submitting it by YE is a hollow win".

      An AD MAA for Europe where only a handful of AD drugs have been approved in decades, which has high approval rates due to a lot of discussions and vetting pre-submission and for which approval would likely mean massive revenues and subsequant share price increase equals "a hollow win"?
      👍️ 11
      ignatiusrielly35 ignatiusrielly35 11 hours ago
      Artificial deadlines are only important if they have some substantive consequence. In which case they would not be artificial. But I digress. 

      I would feel so much better, if I was short or wrote covered calls, if the EMA filing doesn't occur by x date that would necessarily mean that the data suddenly suck and/or the filing will not occur within y weeks of x date, or ever. Load the short boat. 

      If my wife doesn't come home from work as predicted that means she's likely dead from a car accident. 
      👍️ 1 👎️ 1 👺 1
      WilliamMunny WilliamMunny 11 hours ago
      Actually, power, Anavex has 90 days to file its 10-K this year. Unlike 2022 and 2023, the company's public float was under $700 million on the last day of FQ2, so it is no longer a "large accelerated filer," at least as I read it. Therefore the 10-K (and PR/conference call) in December is no problem for the SEC, whether it is the first business day of Advent or Christmas Eve. Particularly since Thanksgiving is late in the month and would interfere with the PR and conference call, I can't imagine a 10-K filing in November.
      👍️ 5
      Hoskuld Hoskuld 11 hours ago
      LF, they have inexplicably abandoned every other initiative they initially said they would make progress on this year: no PD, no secret indication, no Rett, no [fill in the blank]... They have inexplicably poured everything into this one document and they have not finished it yet and have maybe 15 business days left to do so. IMO, they have wasted another whole year with the exception of schizophrenia program - whose p2 is so tiny that I don't think even tremendous success will lift the share price and create value...

      As you wrote, they will either submit the MAA or they won't...but submitting it by YE is a hollow win: the value of the asset is worn away by yet another year. This is just not done in biopharma - executives work their tails off to maximize the most important asset: time.
      👍️ 6 👏 1 👺 1
      Hoskuld Hoskuld 11 hours ago
      If they had submitted then they would announce. This is a company that has never met a self-imposed timeline and had a terrible failure with Rett program. It was supposed to do so much this year and has done nothing. If they had anything even resembling a win they would PR it immediately.
      👍️ 6 👺 1
      Investor2014 Investor2014 12 hours ago
      Yes and otherwise we are into Feb'ish.
      👎️ 1 👺 1
      La Flaca La Flaca 12 hours ago
      Just trying to piece everything together. AVXL has an opportunity to announce either the start date of 11/28 (which means the MAA was filed and accepted) or the filing of the MAA 11/25, in Dec. and they’d meet their commitment / deadline to file inQ4.
      👍️ 4
      Investor2014 Investor2014 13 hours ago
      The chance of that being true is even better than the rumour of a tea pot orbiting Mars, which could be true. Alas as yet we just can't prove or disprove it.
      👍️ 1 👎️ 1 👺 1
      Hoskuld Hoskuld 13 hours ago
      Maybe it was approved and they are secretly selling 2-73 in Lichtenstein right now. We don't know that is not happening, right?
      👎️ 1 👺 3 😁 1
      La Flaca La Flaca 13 hours ago
      I should clarify that I don't know for a fact that they haven't filed. Maybe they have and will PR the start date of 11/28 referenced by Hosai. 🤨
      👋 1 👍️ 1
      La Flaca La Flaca 13 hours ago
      I'm optimistic. They will either make or miss the deadline for what appears to be the last date of submission with EMA in 2024.

      👍️ 2 🤔 1
      CkFacts CkFacts 14 hours ago
      CHMP is a committee of the EMA , and is responsible for the scientific evaluation of the application dossier . After thorough review of the data the CHMP issues it opinion ( positive or negative ) to the EMA . If review is positive the EMA sends recommendation for approval to European Commission.
      👋 2 👍️ 3
      Hoskuld Hoskuld 14 hours ago
      PW you are spot on. The hype in the post, too, is silly: a report needs to be made and it will be made - there is no promise of anything more than the necessary report.
      👍️ 1
      kund kund 14 hours ago
      Anavex has 75 days to file 10k, company market cap was less than $700mil at the end of fiscal year. ST poster is correct, but there is nothing much to read into it, buffoon want to delay everything as much as possible.
      👺 1 ❌️ 1
      powerwalker powerwalker 14 hours ago
      You trust him why? He is full of s**t ... He did NOT speak to IR. As george noted, it is a 10-K being filed, not the Q, and I believe Anavex has to file within 60 days, which is November 29th. If they don't, they need to file with SEC and explain why.
      👍️ 5
      Hosai Hosai 14 hours ago
      The CHMP meetings are just where they discuss applications that have already been accepted as MAAs as far as I understand.
      I don't believe the CHMP is involved in the 2-3 week period when a submission is processed and 'accepted' and given a start date. It's a more basic administrative checklist exercise. There is no scientific evaluation here.
      CHMP were involved in the eligiblity to submit an application stage which AVXL already passed obv.
      👍️ 7
      CkFacts CkFacts 14 hours ago
      Next CHMP meetings Dec 9-12 ,2024 , Jan 27-30 2025
      👋 1 👍️ 2
      ExtremelyBullishZig ExtremelyBullishZig 16 hours ago
      LOL
      👎️ 1 👺 1
      Hosai Hosai 16 hours ago
      I believe the last 2 start dates of this year will be around Nov 28th and Dec 27th going from previous MAA start dates recently and in prior years in that ongoing CHMP apps tracker s/s. Usually the acceptance PR is on the day of the start date or a few days after it.
      👍️ 5
      Investor2014 Investor2014 17 hours ago
      It would make sense for Anavex to announce an accepted MAA, which might be doable in December provided of course the company has actually filed one.
      👍️ 2 👎️ 1 👺 1
      georgejjl georgejjl 17 hours ago
      La Flaca,

      It is NOT a 10Q will be a 10K, since Anavex Life Sciences fiscal year ended on September 30, 2024.

      Good luck and GOD bless,
      👍️0
      La Flaca La Flaca 17 hours ago
      Brian5220 from stocktwits:

      "Okay... Just got off the phone with Anavex IR. They will give a weeks notice before the 10-Q release. IR states it will be in December. Not next week for the conference call or release of the 10-Q."

      Cancel your sell limit. Don't say no one warned you. 🙏





      👍️ 1 🤔 2
      BDR10 BDR10 17 hours ago
      Aren't we all here for the same reason there's no need to have all the fighting and arguing on the board can't we all just get along LOL
      👍️ 2
      Hoskuld Hoskuld 17 hours ago
      No. Trial size adequacy is NOT baked into the p values. (little p instead of big because it is lowercase rho that = stat sig.) So why is this not true? Answer: because for huge indications, like AD, you need a huge sample set to be sure of safety. It is possible that Anavex can overcome this with OLE data and safety data from Rett and other trials.

      You could (easily) say the trial size was inadequate because ADL impact (one of only two primary endpoints) was not stat sig and adding even another 100 patients would have pushed it where it needed to be.

      No one should have a bias where they think everything is honky dory with respect the Anavex and its trials designs and executions. We all want our stock investment to succeed but it doesn't do us any good to only see rainbows and unicorns whenever we examine Anavex's track record.

      Anavex still hasn't done a damn thing. LFG Anavex - execute now please.
      👍️ 6
      powerwalker powerwalker 18 hours ago
      Very nice find, badger. Surprised it took 20+ days for us to see it, given the number of "all things Anavex" people who keep an eye out for publications. It would be good to know which trial these folks are from" P2a or P2b/3 or if it is a mix. More of these testimonials would be great to see.
      👍️ 7

      Your Recent History

      NASDAQ
      AVXL
      Anavex Life Sciences
      ASX
      CBA
      Commonwealth Bank Of Aus...
      Delayed Upgrade Clock